Create Account | Sign In: Author or Forum

Search Symptoms

Category: Cardiology | Family Medicine | Geriatrics | Internal Medicine | Nursing | Pharmacy | Pulmonology | Journal

Back to Journal Articles

Beta-Blockers Cut Mortality for Patients in Sinus Rhythm

Last Updated: June 13, 2017.

For patients with heart failure with reduced ejection fraction in sinus rhythm, beta-blockers reduce mortality regardless of pre-treatment heart rate, according to a study published in the June 20 issue of the Journal of the American College of Cardiology.

TUESDAY, June 13, 2017 (HealthDay News) -- For patients with heart failure with reduced ejection fraction in sinus rhythm, beta-blockers reduce mortality regardless of pre-treatment heart rate, according to a study published in the June 20 issue of the Journal of the American College of Cardiology.

Dipak Kotecha, M.B.B.S., Ph.D., from the University of Birmingham Institute of Cardiovascular Sciences in the United Kingdom, and colleagues conducted a meta-analysis of harmonized individual patient data from 11 double-blind randomized controlled trials involving patients with heart failure with reduced ejection fraction.

The researchers found that for patients in sinus rhythm, a higher heart rate at baseline correlated with greater all-cause mortality (adjusted hazard ratio [HR], 1.11 per 10 beats/minute; 95 percent confidence interval [CI], 1.07 to 1.15; P < 0.0001); this was not seen for patients with atrial fibrillation (AF) (HR, 1.03 per 10 beats/minute; 95 percent CI, 0.97 to 1.08; P = 0.38). In both sinus rhythm and AF, beta-blockers reduced ventricular rate by 12 beats/minute. For patients in sinus rhythm randomized to beta-blockers, mortality was lower (HR, 0.73 versus placebo; 95 percent CI, 0.67 to 0.79; P < 0.001) regardless of heart rate (interaction P = 0.35). For patients with AF, beta-blockers had no impact on mortality (HR, 0.96; 95 percent CI, 0.81 to 1.12; P = 0.58) at any heart rate (interaction P = 0.48).

"Achieving a lower heart rate is associated with better prognosis, but only for those in sinus rhythm," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including Menarini Farmaceutica Internazionale and GlaxoSmithKline.

Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)


Previous: Food Cravings Down With Extended Calorie Restriction Next: Sodium Intake Not Linked to Multiple Sclerosis Progression

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion: